E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
Naval Daver,Sreyashi Basu,Guillermo Garcia-Manero,Hussein A. Abbas,Marina Konopleva,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Ahmad S. Alotaibi,Naveen Pemmaraju,Elias Jabbour,Sherry Pierce,Mark Brandt,Koichi Takahashi,Jing Ning,Steven M. Kornblau,Koji Sasaki,Musa Yilmaz,Ghayas C. Issa,Nicholas J. Short,Jairo Matthews,Wilmer Flores,Michael Andreeff,Jorge E. Cortes,Farhad Ravandi,James P. Allison,Hagop M. Kantarjian,Padmanee Sharma +27 more
TL;DR: AZA+Nivo induced novel and expanded T cell clonotypes, almost exclusively in Rs, which may be a pre-requisite of response to PD1 based therapies, as PD1 inhibitors have limited ability to mobilize peripheral T-cells.
Journal ArticleDOI
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
TL;DR: Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients and should be considered for allogeneic stem cell transplant.
Journal ArticleDOI
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
Iman Abou Dalle,Jorge E. Cortes,Pramod Pinnamaneni,Betty Lamothe,Adolfo Enrique Diaz Duque,Jasleen K. Randhawa,Naveen Pemmaraju,Elias Jabbour,Alessandra Ferrajoli,William G. Wierda,Zeev Estrov,Marina Konopleva,Farhad Ravandi,Yesid Alvarado,Gautam Borthakur,Varsha Gandhi,Hagop M. Kantarjian +16 more
TL;DR: The main reason for treatment discontinuation was disease progression in 26 patients (90%).
Journal ArticleDOI
Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations
Iman Aboudalle,Hagop M. Kantarjian,Maro Ohanian,Yesid Alvarado,Elias Jabbour,Guillermo Garcia-Manero,Kiran Naqvi,William G. Wierda,Naval Daver,Jan A. Burger,Marina Konopleva,Koichi Takahashi,Michael Andreeff,Naveen Pemmaraju,Alessandra Ferrajoli,Gautam Borthakur,Tapan M. Kadia,Farhad Ravandi,Jorge E. Cortes +18 more
TL;DR: The primary objective was to determine the dose limiting toxicity (DLT) and maximal tolerated dose of crenolanib-based combinations, as well as overall response rates (ORR), including complete remission (CR), CR with incomplete blood count recovery (CRi), and partial remission (PR).
Journal ArticleDOI
Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia
Lisa J. McGarry,Y.J. Chen,Victoria Divino,Shibani Pokras,Catherine R. Taylor,J. Munakata,Christopher Nieset,Hui Huang,Elias Jabbour,Daniel C. Malone +9 more
TL;DR: The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure, with a significant increase in unadjusted HCRU over 1year post-failure.